Unmet clinical needs often serve as the fundamental driving force behind drug discovery programs. During lead discovery, an intensive search ensues to find a drug-like small molecule or biological ...
Science Reports of the Tokyo Kyoiku Daigaku, Section A, Vol. 9, No. 220/231 (January 20, 1968), pp. 218-235 (18 pages) ...
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the stocks on Jim Cramer’s radar recently. When a caller asked about ...
SALT LAKE CITY--(BUSINESS WIRE)--Recursion, a tech-enabled biopharma company combining automated, experimental biology with artificial intelligence to discover novel treatments that extend beyond our ...
Recursion Pharmaceuticals (NASDAQ:RXRX) has experienced notable share price fluctuations in 2025, falling 27% year-to-date and trading over 55% beneath its 52-week high of $12. In spite of this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback